Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556425 · ClinicalTrials.gov registry record · Phase 2
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT01556425: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT01556425 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556425, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
In this 5-year study, the investigators propose to evaluate the separate and combined effects of the FDA-approved formulation of extended release naltrexone (Vivitrol®) and employment-based reinforcement of opiate abstinence in promoting opiate abstinence and reducing risky injection behavior in recently detoxified, opioid-dependent, injection drug users.
Interventions
- OTHER Usual Care Control
- DRUG Vivitrol
- BEHAVIORAL Employment-based opiate abstinence reinforcement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-05 |
| Est. Completion | 2017-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01556425
The ClinicalTrials.gov registry entry for NCT01556425 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Usual Care Control is the first listed.
NCT01556425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01556425 about?
NCT01556425 is a clinical study titled "The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence". In this 5-year study, the investigators propose to evaluate the separate and combined effects of the FDA-approved formulation of extended release naltrexone (Vivitrol®) and employment-based reinforcement of opiate abstinence in promoting opiate abstinence and reducing risky injection behavior in rec...
What is the current status of trial NCT01556425?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2012-05. Estimated completion is 2017-08-06.
What interventions are being tested in trial NCT01556425?
The interventions under investigation include: Usual Care Control (OTHER), Vivitrol (DRUG), Employment-based opiate abstinence reinforcement (BEHAVIORAL).
Who is sponsoring clinical trial NCT01556425?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.